[go: up one dir, main page]

DE60237704D1 - Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden - Google Patents

Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden

Info

Publication number
DE60237704D1
DE60237704D1 DE60237704T DE60237704T DE60237704D1 DE 60237704 D1 DE60237704 D1 DE 60237704D1 DE 60237704 T DE60237704 T DE 60237704T DE 60237704 T DE60237704 T DE 60237704T DE 60237704 D1 DE60237704 D1 DE 60237704D1
Authority
DE
Germany
Prior art keywords
hiv
antibodies
antibody fragments
nucleic acids
env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237704T
Other languages
English (en)
Inventor
Dimiter S Dimitrov
Maxime Moulard
Xiadong Xiao
Yuuei Shu
Sanjay K Phogat
Mei-Yun Zhang
Dennis Burton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GOVERNMENT OF US SECRETARY
Scripps Research Institute
US Department of Health and Human Services
Original Assignee
GOVERNMENT OF US SECRETARY
Scripps Research Institute
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GOVERNMENT OF US SECRETARY, Scripps Research Institute, US Department of Health and Human Services filed Critical GOVERNMENT OF US SECRETARY
Application granted granted Critical
Publication of DE60237704D1 publication Critical patent/DE60237704D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60237704T 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden Expired - Lifetime DE60237704D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32970901P 2001-10-16 2001-10-16
PCT/US2002/033165 WO2003033666A2 (en) 2001-10-16 2002-10-16 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes

Publications (1)

Publication Number Publication Date
DE60237704D1 true DE60237704D1 (de) 2010-10-28

Family

ID=23286644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237704T Expired - Lifetime DE60237704D1 (de) 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden

Country Status (7)

Country Link
US (2) US7223844B2 (de)
EP (1) EP1450857B1 (de)
AT (1) ATE481109T1 (de)
AU (1) AU2002337885B1 (de)
CA (1) CA2463931A1 (de)
DE (1) DE60237704D1 (de)
WO (1) WO2003033666A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176037B2 (en) 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US6951947B2 (en) 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
AU2003223517A1 (en) * 2002-04-09 2003-10-27 Children's Hospital, Inc. Antibody gene transfer and recombinant aav
AU2003239356B2 (en) 2002-05-06 2009-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
CA2525370A1 (en) * 2003-05-06 2004-11-25 The Scripps Research Institute Domain-exchanged binding molecules, methods of use and methods of production
AU2004321500A1 (en) * 2003-09-29 2006-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulins with potent and broad antiviral activity
EP1735453A2 (de) 2004-03-12 2006-12-27 The Scripps Research Institute Fluoreszenz-signale abgebende biosensor-moleküle und farbstoffe in lebenden zellen zum nachweis und zur quantifizierung von protein aktivitäten
WO2005111621A2 (en) * 2004-04-16 2005-11-24 Uab Research Foundation Molecular scaffolds for hiv-1 epitopes
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
WO2006091455A2 (en) 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
EP1910573B1 (de) * 2005-07-22 2013-09-04 CytoDyn, Inc. Verfahren zur reduzierung der viruslast in mit hiv-1 infizierten patienten
BRPI0715794A2 (pt) 2006-08-17 2013-07-23 Hoffmann La Roche conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
CA2667358A1 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
SI2417156T1 (sl) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
MX340556B (es) * 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
US9566352B2 (en) 2010-09-27 2017-02-14 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
RS62304B1 (sr) 2013-03-14 2021-09-30 Macrogenics Inc Bispecifični molekuli koji su imunoreaktivni sa imunim efektorskim ćelijama koje eksprimiraju aktivirajući receptor
EP3027755B1 (de) * 2013-08-02 2019-10-09 The Regents of The University of California Manipulation von antiviraler t-zell-immunität durch stammzellen und chimäre antigenrezeptoren
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3055329B1 (de) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispezifische antikörper mit domänengetauschten, gemeinsamen, variablen leichten ketten
EP3080156A1 (de) * 2013-12-10 2016-10-19 F. Hoffmann-La Roche AG Verwendung der bindungsdomäne einer untereinheit einer struktur mit mehreren untereinheiten zur gezielten verabreichung pharmazeutischer wirkstoffe an die struktur mit mehreren untereinheiten
JP6533534B2 (ja) 2014-02-14 2019-06-19 マクロジェニクス，インコーポレーテッド 膠芽腫の治療に使用するための組成物及びその使用
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3641806A4 (de) 2017-06-22 2021-06-23 University of Maryland, Baltimore Breit neutralisierende antikörper gegen hiv
EP3762033A4 (de) * 2018-03-09 2021-12-08 Atreca, Inc. Anti-hiv-antikörper
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
WO1993015747A1 (en) 1992-02-10 1993-08-19 Progenics Pharmaceuticals, Inc. A method of using cd4-containing molecules to substantially reduce the risk of occupational hiv transmission
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ES2194015T3 (es) 1992-09-30 2003-11-16 Scripps Research Inst Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
US5925741A (en) * 1992-12-31 1999-07-20 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
US5843454A (en) * 1993-05-07 1998-12-01 Akzo Nobel N.V. HIV immunogenic complexes
EP0724651B1 (de) 1993-10-19 2008-08-20 The Scripps Research Institute Synthetische humane neutralisierende monoklonale antikörper gegen hiv
CA2204863A1 (en) 1994-11-10 1996-05-23 Dennis R. Burton Method for identifying protective antigens for eliciting neutralizing antibodies
CA2292760A1 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Vector
WO1999024464A1 (en) 1997-11-10 1999-05-20 Dana-Farber Cancer Institute, Inc Glycosylated modified primate lentivirus envelope polypeptides
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
CA2359892A1 (en) 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
EP1161455B1 (de) 1999-03-16 2008-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
EP1054018B1 (de) 1999-05-18 2009-01-28 Dyax Corp. Fab Fragmentbibliotheken und Verfahren für deren Verwendung
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
CA2423127A1 (en) 2000-09-22 2002-03-28 Duke University Immunogen comprising ligand bound hiv envelope protein
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE10123041A1 (de) 2001-05-11 2002-11-28 Tobias Heintges Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
AU2003239356B2 (en) 2002-05-06 2009-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies

Also Published As

Publication number Publication date
WO2003033666A2 (en) 2003-04-24
ATE481109T1 (de) 2010-10-15
AU2002337885B1 (en) 2003-04-28
US7378093B2 (en) 2008-05-27
US20070212349A1 (en) 2007-09-13
EP1450857A4 (de) 2006-01-18
EP1450857B1 (de) 2010-09-15
EP1450857A2 (de) 2004-09-01
WO2003033666A3 (en) 2004-06-24
US20040259075A1 (en) 2004-12-23
US7223844B2 (en) 2007-05-29
CA2463931A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
DE60237704D1 (de) Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2005000244A3 (en) Methods and compositions for treating rheumatoid arthritis
EP2400021A3 (de) Verfahren und Zusammensetzungen auf ErbB3-Basis zur Behandlung von Neoplasmen
WO2003048083A3 (en) Antibodies against monocyte chemotactic proteins
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2002030460A3 (en) Therapeutic antibodies
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
ATE414725T1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
WO2006066078A3 (en) Fcϝriib-specific antibodies and methods of use thereof
EP1064308A4 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
GEP20074252B (en) Antibodies to vla-1
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
WO2004083249A3 (en) Antibodies against human il-21 receptor and uses therefor
TW200621754A (en) Chemical compounds
WO2022032006A9 (en) Il2rb binding molecules and methods of use
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
WO2003048207A3 (en) Anti-dota antibody
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
Walker et al. High-throughput B cell epitope determination by next-generation sequencing
Ntumngia et al. Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
WO2004024075A3 (en) Chemokine receptor antagonists as therapeutic agents
DK1567018T3 (da) Fremgangsmåde til at forbedre immunfunktionen hos pattedyr ved anvendelse af lactobacillus reuteri stammer
WO2004067564B1 (en) Compositions against cancer antigen liv-1 and uses thereof